X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3126) 3126
index medicus (2457) 2457
calcineurin inhibitors (2354) 2354
transplantation (1854) 1854
male (1735) 1735
female (1584) 1584
immunosuppressive agents - therapeutic use (1284) 1284
middle aged (1267) 1267
immunosuppressive agents - adverse effects (1204) 1204
adult (1191) 1191
surgery (1151) 1151
tacrolimus (1128) 1128
cyclosporine (886) 886
kidney transplantation (823) 823
treatment outcome (772) 772
immunosuppression (768) 768
immunology (753) 753
calcineurin (693) 693
immunosuppressive agents - administration & dosage (631) 631
graft rejection - prevention & control (613) 613
aged (610) 610
risk factors (608) 608
recipients (597) 597
mycophenolate-mofetil (576) 576
animals (571) 571
tacrolimus - adverse effects (565) 565
sirolimus (560) 560
kidneys (559) 559
retrospective studies (506) 506
tacrolimus - therapeutic use (506) 506
calcineurin inhibitor (496) 496
kidney transplantation - adverse effects (495) 495
time factors (464) 464
tacrolimus - administration & dosage (429) 429
pharmacology & pharmacy (426) 426
cyclosporine - adverse effects (421) 421
adolescent (399) 399
sirolimus - therapeutic use (399) 399
immunosuppressive agents (392) 392
drug therapy, combination (389) 389
organ transplant recipients (385) 385
child (383) 383
immunotherapy (382) 382
cyclosporine - therapeutic use (379) 379
transplants & implants (370) 370
urology & nephrology (367) 367
mycophenolic acid - analogs & derivatives (358) 358
analysis (355) 355
liver transplantation (351) 351
kidney-transplantation (350) 350
follow-up studies (346) 346
therapy (336) 336
cyclosporine-a (322) 322
dermatology (319) 319
liver (319) 319
health aspects (318) 318
young adult (307) 307
everolimus (306) 306
graft rejection (305) 305
renal-transplantation (301) 301
mycophenolic acid - therapeutic use (292) 292
calcineurin inhibitors - therapeutic use (287) 287
efficacy (285) 285
prospective studies (284) 284
graft survival - drug effects (280) 280
rapamycin (278) 278
sirolimus - adverse effects (277) 277
calcineurin inhibitors - adverse effects (272) 272
glomerular filtration rate (269) 269
rejection (260) 260
graft rejection - immunology (253) 253
graft survival (253) 253
immunosuppressive agents - pharmacology (251) 251
kidney transplantation - immunology (246) 246
cyclosporine - administration & dosage (236) 236
biopsy (235) 235
corticosteroids (235) 235
liver transplantation - adverse effects (235) 235
medicine & public health (232) 232
children (230) 230
nephrotoxicity (230) 230
mycophenolate mofetil (227) 227
pediatrics (227) 227
heart (224) 224
care and treatment (219) 219
atopic dermatitis (217) 217
prognosis (213) 213
safety (212) 212
conversion (211) 211
kidney - drug effects (211) 211
acute rejection (209) 209
risk-factors (206) 206
pharmacokinetics (204) 204
research (203) 203
child, preschool (197) 197
immunosuppressive agents - pharmacokinetics (194) 194
renal transplantation (193) 193
calcineurin inhibitors - administration & dosage (192) 192
drug therapy (192) 192
patients (190) 190
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3801) 3801
German (30) 30
Spanish (28) 28
Japanese (21) 21
French (15) 15
Korean (8) 8
Italian (6) 6
Chinese (5) 5
Polish (5) 5
Croatian (1) 1
Dutch (1) 1
Finnish (1) 1
Hungarian (1) 1
Russian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Transplantation, ISSN 0041-1337, 2018, Volume 102, Issue 2S Suppl 1, pp. S60 - S70
.... The mammalian target of rapamycin (mTOR) inhibitors, sirolimus and everolimus, are increasingly used after organ transplantation with potential advantages in virus-associated posttransplant malignancies as well as anti-cancer properties... 
SOLID-ORGAN TRANSPLANTATION | SURGERY | RENAL-ALLOGRAFT RECIPIENTS | IMMUNOLOGY | TRANSPLANTATION | PHASE-II TRIAL | TUBEROUS SCLEROSIS COMPLEX | NONMELANOMA SKIN-CANCER | KAPOSIS-SARCOMA | POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS | KIDNEY-TRANSPLANTATION | SQUAMOUS-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | TOR Serine-Threonine Kinases - metabolism | Tumor Virus Infections - virology | Humans | Immunosuppressive Agents - therapeutic use | Neoplasms - prevention & control | Protein Kinase Inhibitors - adverse effects | TOR Serine-Threonine Kinases - antagonists & inhibitors | Neoplasms - virology | Time Factors | Graft Rejection - mortality | Tumor Virus Infections - immunology | Anticarcinogenic Agents - adverse effects | Opportunistic Infections - immunology | Drug Therapy, Combination | Anticarcinogenic Agents - therapeutic use | Organ Transplantation - mortality | Graft Rejection - enzymology | Opportunistic Infections - virology | Graft Rejection - prevention & control | Risk Factors | Neoplasms - mortality | Treatment Outcome | Calcineurin Inhibitors - adverse effects | Animals | Signal Transduction - drug effects | Neoplasms - immunology | Protein Kinase Inhibitors - therapeutic use | Organ Transplantation - adverse effects | Immunosuppressive Agents - adverse effects | Graft Rejection - immunology | Immunocompromised Host | Graft Survival - drug effects | Prevention | Transplantation of organs, tissues, etc | Physiological aspects | Enzyme inhibitors | Carcinogenesis | Patient outcomes | Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 12/2004, Volume 110, Issue 25, pp. 3858 - 3865
Drugs | Rejection | Transplantation | Immune system | CARDIAC & CARDIOVASCULAR SYSTEMS | MYCOPHENOLATE MOFETIL RS-61443 | CYCLOSPORINE MICROEMULSION | TACROLIMUS FK506 | drugs | COMBINATION THERAPY | RANDOMIZED MULTICENTER | RENAL-TRANSPLANTATION | rejection | CLINICAL-EXPERIENCE | RAPAMYCIN AY-22,989 | transplantation | immune system | PERIPHERAL VASCULAR DISEASE | CARDIAC ALLOGRAFT-REJECTION | LIVER-TRANSPLANT | Azathioprine - administration & dosage | Azathioprine - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Adrenal Cortex Hormones - therapeutic use | Antimetabolites - therapeutic use | Mycophenolic Acid - pharmacology | Everolimus | Sirolimus - adverse effects | Antimetabolites - pharmacology | Tacrolimus - administration & dosage | Transplantation, Homologous - adverse effects | Graft Rejection - drug therapy | Heart Transplantation - immunology | Administration, Oral | Adrenal Cortex Hormones - pharmacology | Heart Transplantation - adverse effects | Adrenal Cortex Hormones - adverse effects | Antimetabolites - adverse effects | Cyclosporine - therapeutic use | Protein Kinase Inhibitors - administration & dosage | Growth Inhibitors - administration & dosage | Mycophenolic Acid - analogs & derivatives | Cyclosporine - adverse effects | Cyclosporine - administration & dosage | TOR Serine-Threonine Kinases | Cyclosporine - pharmacology | Calcineurin Inhibitors | Tacrolimus - pharmacology | Mycophenolic Acid - administration & dosage | Growth Inhibitors - pharmacology | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - administration & dosage | Protein Kinases - drug effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Graft Rejection - prevention & control | Azathioprine - pharmacology | Clinical Trials as Topic | Tacrolimus - adverse effects | Sirolimus - pharmacology | Transplantation, Homologous - immunology | Antimetabolites - administration & dosage | Growth Inhibitors - therapeutic use | Mycophenolic Acid - adverse effects | Sirolimus - administration & dosage | Tacrolimus - therapeutic use | Mycophenolic Acid - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Immunosuppressive Agents - adverse effects | Protein Kinase Inhibitors - pharmacology | Growth Inhibitors - adverse effects | Azathioprine - adverse effects | Adrenal Cortex Hormones - administration & dosage
Journal Article
Transplantation, ISSN 0041-1337, 08/2016, Volume 100, Issue 8, pp. 1723 - 1731
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2007, Volume 357, Issue 25, pp. 2562 - 2575
Background: Immunosuppressive regimens with the fewest possible toxic effects are desirable for transplant recipients... 
MULTICENTER TRIAL | MEDICINE, GENERAL & INTERNAL | CYCLOSPORINE MICROEMULSION | EFFICACY | KIDNEY-TRANSPLANTATION | IMMUNOSUPPRESSION | ALLOGRAFT RECIPIENTS | TACROLIMUS | MYCOPHENOLATE-MOFETIL | SIROLIMUS | NEPHROTOXICITY | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Adrenal Cortex Hormones - therapeutic use | Enzyme Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized | Calcineurin Inhibitors | Treatment Failure | Adult | Diabetes Mellitus - etiology | Female | Drug Therapy, Combination | Mycophenolic Acid - administration & dosage | Immunosuppressive Agents - administration & dosage | Sirolimus - adverse effects | Tacrolimus - administration & dosage | Prednisone - administration & dosage | Glomerular Filtration Rate | Graft Rejection - prevention & control | Kaplan-Meier Estimate | Kidney Transplantation | Immunoglobulin G - administration & dosage | Opportunistic Infections | Sirolimus - administration & dosage | Mycophenolic Acid - analogs & derivatives | Antibodies, Monoclonal - administration & dosage | Cyclosporine - administration & dosage | Immunosuppressive Agents - adverse effects | Aged | Adrenal Cortex Hormones - administration & dosage | Transplantation | Corticosteroids | Kidneys | Research | Health aspects | Immunosuppressive agents | Medical research | Immunology | Inhibitor drugs | Transplants & implants | Toxicity | Inhibidors enzimàtics | Posologia | Ús terapèutic | Corticosteroides | Rebuig (Biologia) | Posology | Therapeutic use | Immunosupressive agents | Graft rejection | Trasplantament renal | Enzyme inhibitors | Adrenocortical hormones | Immunosupressors | Kidney transplantation | Tacrolimus: administration & dosage | Medical and Health Sciences | Graft Rejection: prevention & control | Immunoglobulin G: administration & dosage | Medicin och hälsovetenskap | Mycophenolic Acid: administration & dosage | Antibodies | Klinisk medicin | Monoclonal: administration & dosage | Prednisone: administration & dosage | Adrenal Cortex Hormones: administration & dosage | Immunosuppressive Agents: administration & dosage | Mycophenolic Acid: analogs & derivatives | Sirolimus: administration & dosage | Cyclosporine: administration & dosage | Calcineurin: antagonists & inhibitors | Diabetes Mellitus: etiology | Urologi och njurmedicin | Sirolimus: adverse effects | Adrenal Cortex Hormones: therapeutic use | Enzyme Inhibitors: administration & dosage | Immunosuppressive Agents: adverse effects | Clinical Medicine | Immunosuppressive Agents: therapeutic use | Urology and Nephrology
Journal Article
Transplantation, ISSN 0041-1337, 2009, Volume 87, Issue 2, pp. 233 - 242
Journal Article
American Journal of Transplantation, ISSN 1600-6135, 08/2009, Volume 9, Issue 8, pp. 1936 - 1945
This randomized, pilot study compared the Janus kinase inhibitor CP-690,550 (15 mg BID [CP15] and 30 mg BID [CP30], n = 20 each) with tacrolimus (n = 21) in de novo kidney allograft recipients... 
kidney | immunosuppression | transplant | inhibitor | Janus kinase (JAK) | CP-690,550 | CP‐690,550 | Immunosuppression | Inhibitor | Kidney | Transplant | NONHUMAN-PRIMATES | SURGERY | RENAL-TRANSPLANTATION | TRANSPLANTATION | 550 | REJECTION | CP-690 | MYCOPHENOLATE-MOFETIL | SIROLIMUS | Kidney Transplantation - pathology | Follow-Up Studies | Kidney - pathology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Adrenal Cortex Hormones - therapeutic use | Glomerular Filtration Rate - physiology | Transplantation, Homologous | Dose-Response Relationship, Drug | Young Adult | Calcineurin Inhibitors | Kidney Transplantation - physiology | Piperidines | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Kidney - physiopathology | Graft Rejection - prevention & control | Kaplan-Meier Estimate | Tacrolimus - adverse effects | Janus Kinases - antagonists & inhibitors | Adrenal Cortex Hormones - adverse effects | Mycophenolic Acid - adverse effects | Tacrolimus - therapeutic use | Pilot Projects | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Biopsy | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Graft Rejection - immunology | Kidney Transplantation - immunology | Virus diseases | Medical colleges | Kidneys | Tacrolimus | Anemia | Immunotherapy | Transplantation | Kidney diseases | Health aspects | Index Medicus
Journal Article
The Journal of immunology (1950), ISSN 1550-6606, 2013, Volume 191, Issue 12, pp. 5785 - 5791
Calcineurin inhibitors (CNIs) revolutionized the field of organ transplantation and remain the standard of care 40 years after the discovery of cyclosporine... 
COSTIMULATION BLOCKADE | ATOPIC-DERMATITIS | ADULT PATIENTS | CYCLOSPORINE-A | PHASE-III | REGULATORY T-CELLS | MEMBRANOUS NEPHROPATHY | RANDOMIZED-TRIAL | TACROLIMUS OINTMENT | IMMUNOLOGY | RENAL-TRANSPLANT RECIPIENTS | Meta-Analysis as Topic | History, 21st Century | Cyclosporine - pharmacology | Humans | Immunosuppressive Agents - therapeutic use | Tacrolimus - history | Calcineurin Inhibitors | Multicenter Studies as Topic | Immunosuppressive Agents - history | T-Lymphocytes - drug effects | Kidney Diseases - chemically induced | Tacrolimus - pharmacology | Drug Evaluation, Preclinical | Drug Therapy, Combination | Immunosuppressive Agents - pharmacology | Autoimmune Diseases - drug therapy | Cyclosporine - history | Kidney Transplantation - history | Graft Rejection - prevention & control | History, 20th Century | Tacrolimus - chemistry | Kidney Diseases - drug therapy | Clinical Trials as Topic | Tacrolimus - adverse effects | Forecasting | Randomized Controlled Trials as Topic | Calcineurin - physiology | Kidney Diseases - immunology | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Animals | Cyclosporine - chemistry | Lymphocyte Activation - drug effects | Cyclosporine - adverse effects | Immunosuppressive Agents - adverse effects | T-Lymphocytes - immunology | Diabetes Mellitus, Type 2 - chemically induced | Immunosuppressive Agents - chemistry | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 3, pp. 494 - 503.e6
Journal Article